Self-Assembled RNA Nanostructures for Endosomal Escape in Cancer Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current siRNA treatments for cancer are ineffective due to the lack of effective delivery methods to cancer cells and the trapping of siRNA in endosomes.
Innovation Solution
A therapeutic RNA complex composed of synthetic double-stranded RNA oligonucleotides with a cholesterol molecule at the 3' end of the sense strand, designed to self-assemble into RNA nanostructures, which effectively deliver siRNA to cells and release it inside the cell by digesting the sense strand.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If siRNA is delivered to cancer cells using conventional methods, then the siRNA can be introduced into cells, but the siRNA gets trapped in endosomes and cannot reach the cytoplasm effectively
Solution Approach 1:
The patent uses an endosomolytic agent as an intermediary substance that facilitates the release of siRNA from endosomes. This agent mediates the interaction between the endosomal membrane and the siRNA complex, enabling escape from endosomal trapping and delivery to the cytoplasm.
Solution Approach 2:
The patent modifies the chemical parameters of the siRNA complex by incorporating lipid components with specific properties (positive charge, endosomolytic activity). These parameter changes enable the complex to interact with and disrupt endosomal membranes, overcoming the trapping problem.
2Reliability
If siRNA is delivered without specialized structures, then the delivery system is simple, but the siRNA cannot effectively reach and act on target cancer cells
Solution Approach 1:
The patent creates a composite nanostructure combining siRNA with lipid components that have specific functions (transfection, endosomolysis). This composite material integrates multiple functionalities into a single delivery system, improving cellular delivery efficiency while managing complexity through functional integration.
Solution Approach 2:
The lipid-based nanostructure serves multiple functions simultaneously: protecting siRNA from degradation, facilitating cellular uptake, enabling endosomal escape, and promoting cytoplasmic delivery. This multi-functionality resolves the contradiction by achieving high delivery efficiency through a single integrated system.
3Reliability
If conventional siRNA delivery methods are used, then the treatment approach is simple, but the treatment shows ineffectiveness in cancer therapy
Solution Approach 1:
The patent segments the delivery system into distinct functional components: siRNA for gene silencing, lipid envelope for protection and delivery, and endosomolytic agents for escape. This segmentation allows optimization of each component's function while achieving overall therapeutic effectiveness.
Solution Approach 2:
The patent employs composite materials combining nucleic acids with lipid-based structures to create a theranostic platform that achieves both delivery and therapeutic effects, resolving the ineffectiveness of conventional simple approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA complex efficiently delivers siRNA to cancer cells, overcoming endosomal trapping and achieving significant cytotoxicity and metastasis inhibition in animal models.
Implementation Method 1
the trapping of siRNA in endosomes
Implementation Method 2
release it inside the cell by digesting the sense strand
Data Source
AI summary
Disclosed herein are compositions and methods for one step CMC production of RNA therapeutic complexes (nanostructures) that contain nucleoside analogues. In some embodiments, the nucleoside analogues are incorporated into RNA oligonucleotides that self-assemble into an RNA complex during RNA synthesis in a one-step production. Therefore, no additional conjugation or synthesis processes are required.